[en] [en] OBJECTIVE: The objective of the study was to assess the tolerability and safety of galcanezumab in patients with chronic cluster headache (CH) with up to 15 months of treatment.
BACKGROUND: Chronic CH is a highly debilitating disease with a substantial and unmet medical need.
METHODS: Patients were randomized to receive placebo or galcanezumab (300 mg) monthly for 12 weeks, followed by an optional 52-week open-label extension and 16-week posttreatment follow-up (washout). This is a secondary analysis and long-term follow-up of a previously conducted clinical trial. The safety analysis included patients who received galcanezumab at any time during the study. Outcomes included adverse events (AEs), discontinuations, laboratory values, vital signs, electrocardiograms (ECGs), and suicidality ratings.
RESULTS: A total of 233 patients received at least one galcanezumab dose. The mean exposure was 341 days. Galcanezumab-treated patients were mostly male (n = 169/233; 72.5%) with a mean age of 44.9 (±10.9) years. Treatment-emergent adverse events (TEAEs) were reported by 185 patients (n = 185/233; 79.4%), 23 patients (n = 23/233; 9.9%) reported serious adverse events (SAEs), and 18 patients (n = 18/233; 7.7%) discontinued due to AEs. The SAE CH was reported by three patients. The most common TEAEs (>10%) were nasopharyngitis (n = 41/233; 17.6%) and injection site pain (n = 33/233; 14.2%). 27.5% of patients (n = 64/233) had TEAEs related to injection sites. Likely hypersensitivity events, including injection site rash, injection site urticaria, and injection site hypersensitivity were reported (n = 14/233; 6.0%). There were past histories of suicidal ideation (n = 55/237; 23.2%) and suicidal behavior (n = 9/236; 3.8%). During the study, 15 patients (n = 15/230; 6.5%), seven with previous history, reported suicidal ideation. One patient had a nonfatal suicide attempt during the open-label extension and an aborted attempt during the washout. There were no new safety findings compared with the placebo-controlled treatment period in laboratory values, vital signs, or ECGs.
CONCLUSIONS: Galcanezumab 300 mg monthly had a favorable tolerability and safety profile in patients with chronic CH with up to 15 months of treatment.
Disciplines :
Neurology
Author, co-author :
Láinez, Miguel J A; Hospital Clinico Universitario, Universidad Católica de Valencia, Valencia, Spain
Schoenen, Jean ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques
Stroud, Chad; Eli Lilly and Company, Indianapolis, Indiana, USA
Bardos, Jennifer; Eli Lilly and Company, Indianapolis, Indiana, USA
Bangs, Mark; Eli Lilly and Company, Indianapolis, Indiana, USA
Kemmer, Phebe; Eli Lilly and Company, Indianapolis, Indiana, USA
Wenzel, Richard; Eli Lilly and Company, Indianapolis, Indiana, USA
Kuruppu, Dulanji K; Eli Lilly and Company, Indianapolis, Indiana, USA
Martinez, James Michael; Eli Lilly and Company, Indianapolis, Indiana, USA
Oakes, Tina M; Eli Lilly and Company, Indianapolis, Indiana, USA
Language :
English
Title :
Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment.
Chad Stroud, Jennifer Bardos, Mark Bangs, Phebe Kemmer, Richard Wenzel, Dulanji K. Kuruppu, James Michael Martinez, and Tina M. Oakes are employees and minor stockholders of Eli Lilly and Company. Miguel J. A. Láinez has received honoraria, consultation fees, and research grants from Allergan, Amgen, Bayer, Bial, Boehringher, Chiesi, ElectroCore, Eli Lily, Medtronic, Novartis, Otsuka, PRIM, Roche, Teva, and UCB. Jean Schoenen has received honoraria and speaker's fees from Teva, Novartis, Eli Lilly, Allergan, Amgen, Electrocore, Cefaly Technology, and Man & Science.This work is sponsored by Eli Lilly and Company
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1-211.
Ji Lee M, Cho SJ, Wook Park J, et al. Increased suicidality in patients with cluster headache. Cephalalgia. 2019;39:1249-1256.
Rozen TD, Fishman RS. Cluster headache in the United States of America: demographics, clinical characteristics, triggers, suicidality, and personal burden. Headache. 2012;52:99-113.
Brandt RB, Doesborg PGG, Haan J, Ferrari MD, Fronczek R. Pharmacotherapy for cluster headache. CNS Drugs. 2020;34:171-184.
May A, Leone M, Áfra J, et al. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol. 2006;13:1066-1077.
Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ. Treatment of cluster headache: the American Headache Society evidence-based guidelines. Headache. 2016;56:1093-1106.
Akins PT. Does mild cognitive impairment represent early-stage Alzheimer disease? Arch Neurol. 2001;58:1705-1706.
Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383-421.
Dodick DW, Goadsby PJ, Lucas C, et al. Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: results from 3-month double-blind treatment. Cephalalgia. 2020;40(9):935-948.
Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, Edvinsson L. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience. 2010;169:683-696.
Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010;6:573-582.
Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94:1099-1142.
Iyengar S, Ossipov MH, Johnson KW. The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain. 2017;158:543-559.
Bangs ME, Kudrow D, Wang S, et al. Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies. BMC Neurol. 2020;20:25.
Oakes TM, Kovacs R, Rosen N, et al. Evaluation of cardiovascular outcomes in adult patients with episodic or chronic migraine treated with galcanezumab: data from three phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. Headache. 2020;60:110-123.
Akazawa K, Kamakura T, Sakamoto M, Odaka T, Nose Y. Patient registration and treatment allocation in multicenter clinical trials using a FAX-OCR system. Methods Inf Med. 1994;33:530-534.
Goadsby PJ, Dodick DW, Leone M, et al. Trial of galcanezumab in prevention of episodic cluster headache. N Engl J Med. 2019;381:132-141.
Lamb YN. Galcanezumab: first global approval. Drugs. 2018;78:1769-1775.
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629-808.
Martinez JM, Hindiyeh N, Anglin G, et al. Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine. Cephalalgia. 2020;40:978-989.
Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266-1277.
Fuller RW, Conradson TB, Dixon CM, Crossman DC, Barnes PJ. Sensory neuropeptide effects in human skin. Br J Pharmacol. 1987;92:781-788.
Arulmani U, Schuijt MP, Heiligers JP, Willems EW, Villalon CM, Saxena PR. Effects of the calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS on alpha-CGRP-induced regional haemodynamic changes in anaesthetised rats. Basic Clin Pharmacol Toxicol. 2004;94:291-297.
Zeller J, Poulsen KT, Sutton JE, et al. CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat. Br J Pharmacol. 2008;155:1093-1103.
Groppelli A, Giorgi DM, Omboni S, Parati G, Mancia G. Persistent blood pressure increase induced by heavy smoking. J Hypertens. 1992;10:495-499.
Jullien D, Prinz JC, Nestle FO. Immunogenicity of biotherapy used in psoriasis: the science behind the scenes. J Invest Dermatol. 2015;135:31-38.
Silberstein S, Lenz R, Xu C. Therapeutic monoclonal antibodies: what headache specialists need to know. Headache. 2015;55:1171-1182.
Carrascosa JM. Immunogenicity in biologic therapy: implications for dermatology. Actas Dermosifiliogr. 2013;104:471-479.
Camporeale A, Kudrow D, Sides R, et al. A phase 3, long-term, open-label safety study of galcanezumab in patients with migraine. BMC Neurol. 2018;18:188.
